AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (1.6 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells

Leyi Yao1,2,3,*, Qian Zhao4,*, Ding Yan1,2, Ziying Lei1, Yali Hao1,2, Jinghong Chen2, Qian Xue1,2, Xiaofen Li1,2, Qingtian Huang1,2, Daolin Tang5, Q. Ping Dou6, Xin Chen1,2 ( ), Jinbao Liu1,2,3 ( )
Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, China
Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 511436, China
Institute of Digestive Disease of Guangzhou Medical University, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People’s Hospital, Qingyuan 511518, China
School of Public Health, Guangzhou Medical University, Guangzhou, 511436, China
Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA
Barbara Ann Karmanos Cancer Institute and Departments of Oncology, Pharmacology & Pathology, School of Medicine, Wayne State University, Detroit, MI 48201, USA

*These authors contributed equally to this work.

Show Author Information

Abstract

Objective

Sorafenib is a first-line drug for advanced hepatocellular carcinoma (HCC). Unfortunately, most patients with HCC do not respond to sorafenib, mainly because of the frequent development of drug resistance. Bilirubin is an end metabolite of heme catabolism and an indicator of liver function, but its direct role in regulating the anticancer activity of sorafenib in HCC cells is unclear. In the current study, we aimed to investigate the mechanism of action of bilirubin in sorafenib-mediated tumor suppression in HCC.

Methods

A retrospective observational cohort of 100 patients receiving sorafenib was conducted to evaluate the potential role of bilirubin in predicting the prognosis of patients with HCC. Human HCC cell lines were treated with sorafenib in the absence or presence of bilirubin, and cell proliferation, apoptosis, and signaling pathways were assayed. The antagonistic effect of bilirubin toward sorafenib was assessed in nude mice bearing HCC xenografts.

Results

Serum levels of bilirubin (including total, direct, and indirect bilirubin) negatively correlated with the overall survival of patients with HCC treated with sorafenib (P < 0.05). Both in vitro and in vivo analyses demonstrated that bilirubin significantly abrogated sorafenib-mediated proliferation inhibition and apoptosis induction in HCC cells (P < 0.05). Mechanically, bilirubin inhibited sorafenib-induced activation of GSK-3β and subsequent downstream MCL-1 degradation.

Conclusions

Our study provides experimental evidence of the antagonistic effect of bilirubin toward sorafenib-mediated anticancer activity in HCC, and it suggests that bilirubin could be used to predict the efficacy of sorafenib treatment.

Electronic Supplementary Material

Download File(s)
cbm-19-7-1061_ESM.pdf (89.2 KB)

References

【1】
【1】
 
 
Cancer Biology & Medicine
Pages 1061-1077

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Yao L, Zhao Q, Yan D, et al. Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells. Cancer Biology & Medicine, 2022, 19(7): 1061-1077. https://doi.org/10.20892/j.issn.2095-3941.2021.0598

699

Views

49

Downloads

7

Crossref

7

Web of Science

7

Scopus

Received: 05 November 2021
Accepted: 25 February 2022
Published: 24 May 2022
©2022 Cancer Biology & Medicine.

Creative Commons Attribution-NonCommercial 4.0 International License